No Data
No Data
Tomoshiba Bio-B proposes to adopt the 2024 H-share share option plan
Youzhi YouBio-B (02496) issued an announcement. On May 29, 2024, the board of directors resolved to adopt the 2024 H share option plan in accordance with Chapter 17 of the Listing Rules for shareholders' approval at the company's annual general meeting of shareholders to be held on June 27 (Thursday) 2024. The purpose of the 2024 H share option plan is to: recognize and acknowledge the contributions that eligible participants have made or may have made to the Group; enhance the enthusiasm and loyalty of eligible participants to promote the long-term development of the enterprise and enhance shareholder value; and establish the sharing of interests among employees, shareholders and the company
Tomoshiba Biological-B (02496.HK) proposes to adopt the 2024 H share option plan
Gelonghui, May 29 | Youzhiyou Bio-B (02496.HK) announced that on May 29, 2024, the board of directors decided to recommend the 2024 H share option plan in accordance with Chapter 17 of the Listing Rules for shareholders' approval at the company's annual general meeting of shareholders to be held on June 27, 2024.
Tomoshibayu Biological-B (02496.HK): M701 malignant ascites phase II study data presented at 2024 ASCO conference
Gelonghui, May 24 | Youzhiyou Bio-B (02496.HK) announced that the mid-term analysis data of the Phase I clinical study (“this study”) of the company's self-developed epithelial cell adhesion molecule (“epCAM”) and differentiation cluster 3 (“CD3") dual-targeted bispecific antibody (“BsAb”) drug M701 in China to treat malignant ascites caused by advanced epithelial solid tumors (“this study”) was presented in the 2024 American Society of Clinical Oncology (“ASCO”) abstract meeting in the form of a poster discussion ID: 12060, Poster No.: 189), will also be carried out by the company
YZYBIO-B: 2023 ANNUAL REPORT
YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2023
Tomoshibayu Bio-B (02496.HK): Phase III clinical trial of the bispecific antibody M701 malignant ascites completed the first patient enrollment
On March 27, Ge Longhui | Youzhiyou Bio-B (02496.HK) announced that M701, an investigational bispecific antibody (“BsAb”) that targets both epithelial cell adhesion molecule (“epCAM”) and differentiation cluster 3 (“CD3”) independently developed by the company, recently completed the first case of patients enrolled in a critical phase III registered clinical trial (“malignant ascites study”). The purpose of the malignant ascites study was to evaluate the efficacy and safety of peritoneal perfusion M701 compared with abdominal puncture drainage in patients with malignant ascites caused by advanced solid epithelial tumors. If successful, malignant ascites research will be used to support
No Data